| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8668545 | Journal of Clinical Lipidology | 2017 | 30 Pages |
Abstract
Continued use of evolocumab added to SOC in patients with HeFH yields persistent and marked low-density lipoprotein cholesterol reductions during 48Â weeks of follow-up. Long-term dosing of evolocumab with SOC was safe and well tolerated.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
G. Kees MD, PhD, MBA, Frederick J. MBBCh, PhD, Ricardo MD, Claudia MD, PhD, Olivier MD, PhD, Luis MD, PhD, Armando MD, Ian MSc, Blai MD, David MD,